undefined undefined
NaN.000
NaN.00%
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
05-10 00:40
HOOKIPA Pharma press release (NASDAQ:HOOK): Q1 GAAP EPS of $0.11. Total revenues of $36.6 million, mainly driven by the recognition of previously received upfront and milestone payments under the now-...
05-09 19:57
Hookipa Pharma Inc (HOOK) has shared an update. HOOKIPA Pharma Inc. has unveile...
04-25 19:22
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.
04-15 20:56
12月31日,Hookipa Pharma Inc.(HOOK.US)公布财报,公告显示公司2023财年净利润为-81.58百万美元,同比减少25.66%;其中...
03-23 15:17
Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on Hook...
03-22 23:55
HOOKIPA Pharma (NASDAQ:HOOK) reported its Q4 earnings results on Friday, March ...
03-22 21:20
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 29.41 percent decrease over losses of $(0.17) per share from
03-22 19:03
Graves病(弥漫性毒性甲状腺肿)是一种临床常见的自身免疫性甲状腺疾病,是甲亢最常见的病因。其致病机理为促甲状腺素受体抗体(TRAb)与促甲状腺激素受体(T...
03-08 11:16
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.
01-30 01:55